Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

Abstract Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly d...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. Lahoud, Heather J. Landau, David J. Chung, Gunjan L. Shah, Michael Scordo, Sergio A. Giralt, Alexander Lesokhin, Saad Z. Usmani, Ola Landgren, Neha Korde
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Nature Publishing Group 2023-07-01
سلاسل:	Blood Cancer Journal
الوصول للمادة أونلاين:	https://doi.org/10.1038/s41408-023-00882-y
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!